Hydroxamic acids block replication of hepatitis c virus

Journal of Medicinal Chemistry

Volumn 58, Issue 2, 2015, Pages 785-800

  Ai, Teng ^a   Xu, Yanli ^a   Qiu, Li ^a   Geraghty, Robert J ^a   Chen, Liqiang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) N HYDROXYACRYLAMIDE; 3 (4 CYANOPHENYL) N HYDROXYACRYLAMIDE; ANTIVIRUS AGENT; BENZOTHIOPHENE DERIVATIVE; CINNAMIC HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N (TETRAHYDROPYRAN 2 YLOXY) 3 (2 (TRIFLUOROMETHYL)PHENYL)ACRYLAMIDE; N (TETRAHYDROPYRAN 2 YLOXY) 3 (2 CHLORO 4 (TRIFLUOROMETHYL)PHENYL)ACRYLAMIDE; N (TETRAHYDROPYRAN 2 YLOXY) 3 (2,6 DIFLUORO 4 (TRIFLUOROMETHYL)PHENYL)ACRYLAMIDE; N (TETRAHYDROPYRAN 2 YLOXY) 3 (3 (TRIFLUOROMETHYL)PHENYL)ACRYLAMIDE; N (TETRAHYDROPYRAN 2 YLOXY) 3 (4 METHYLSULFONYL)PHENYL)ACRYLAMIDE; N (TETRAHYDROPYRAN 2 YLOXY) 3 (5 (TRIFLUOROMETHYL)PYRIDIN 2 YL)ACRYLAMIDE; N (TETRAHYDROPYRAN 2 YLOXY) 3 (6 (TRIFLUOROMETHYL)PYRIDIN 3 YL)ACRYLAMIDE; N (TETRHYDROPYRAN 2 YLOXY) 3 (2 FLUORO 4 (TRIFLUOROMETHYL)PHENYL)ACRYLAMIDE; N HYDROXY 3 (4 (METHYLSULFONYL)PHENYL)ACRYLAMIDE; N HYDROXY 3 (4 METHOXYPHENYL)ACRYLAMIDE; N HYDROXY 3 (4 NITROPHENYL)ACRYLAMIDE; N HYDROXY 3 (4 TOLYL)ACRYLAMIDE; N HYDROXY 3 PHENYLBUT 2 ENAMIDE; N HYDROXY 3,3 DIPHENYLACRYLAMIDE; N HYDROXYCINNAMAMIDE; TERT BUTYL 3 (2 (TRIFLUOROMETHYL)PHENYL)ACRYLATE; TERT BUTYL 3 (2 CHLORO 4 (TRIFLUOROMETHYL)PHENYL)ACRYLATE; TERT BUTYL 3 (2 FLUORO 4 (TRIFLUOROMETHYL)PHENYL)ACRYLATE; TERT BUTYL 3 (2,6 DIFLUORO 4 (TRIFLUOROMETHYL)PHENYL)ACRYLATE; TERT BUTYL 3 (4 (METHYLSULFONYL)PHENYL)ACRYLATE; TERT BUTYL 3 (5 (TRIFLUOROMETHYL)PYRIDIN 2 YL)ACRYLATE; TERT BUTYL 3 (6 (TRIFLUOROMETHYL)PYRIDIN 3 YL)ACRYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION; DRUG EFFECTS; HEPACIVIRUS; PHYSIOLOGY; SYNTHESIS;

ANTIVIRAL AGENTS; HEPACIVIRUS; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84921458292     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501330g     Document Type: Article

References (53)

1. Shepard, C. W.; Finelli, L.; Alter, M. J. Global epidemiology of hepatitis C virus infection Lancet Infect. Dis. 2005, 5, 558-567
2. Neukam, K.; Macias, J.; Mira, J. A.; Pineda, J. A. A review of current anti-HCV treatment regimens and possible future strategies Expert. Opin. Pharmacother. 2009, 10, 417-433
3. Herrine, S. K.; Rossi, S.; Navarro, V. J. Management of patients with chronic hepatitis C infection Clin. Exp. Med. 2006, 6, 20-26
4. Thompson, A. J.; McHutchison, J. G. Antiviral resistance and specifically targeted therapy for HCV (STAT-C) J. Viral Hepatitis 2009, 16, 377-387
5. Scheel, T. K.; Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat. Med. 2013, 19, 837-849
6. FDA approves first combination pill to treat hepatitis C. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm418365.htm.
7. Baugh, J. M.; Garcia-Rivera, J. A.; Gallay, P. A. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res. 2013, 100, 555-561
8. Shakespear, M. R.; Halili, M. A.; Irvine, K. M.; Fairlie, D. P.; Sweet, M. J. Histone deacetylases as regulators of inflammation and immunity Trends Immunol. 2011, 32, 335-343
9. Kim, S. C.; Sprung, R.; Chen, Y.; Xu, Y.; Ball, H.; Pei, J.; Cheng, T.; Kho, Y.; Xiao, H.; Xiao, L.; Grishin, N. V.; White, M.; Yang, X. J.; Zhao, Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey Mol. Cell 2006, 23, 607-618
10. Zhao, S.; Xu, W.; Jiang, W.; Yu, W.; Lin, Y.; Zhang, T.; Yao, J.; Zhou, L.; Zeng, Y.; Li, H.; Li, Y.; Shi, J.; An, W.; Hancock, S. M.; He, F.; Qin, L.; Chin, J.; Yang, P.; Chen, X.; Lei, Q.; Xiong, Y.; Guan, K. L. Regulation of cellular metabolism by protein lysine acetylation Science 2010, 327, 1000-1004
11. Ciccaglione, A. R.; Marcantonio, C.; Tritarelli, E.; Tataseo, P.; Ferraris, A.; Bruni, R.; Dallapiccola, B.; Gerosolimo, G.; Costantino, A.; Rapicetta, M. Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones BMC Genomics 2008, 9, 309
12. Miura, K.; Taura, K.; Kodama, Y.; Schnabl, B.; Brenner, D. A. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity Hepatology 2008, 48, 1420-1429
13. Lopez-Rodriguez, R.; Hernandez-Bartolome, A.; Borque, M. J.; Rodriguez-Munoz, Y.; Martin-Vilchez, S.; Trapero-Marugan, M.; Garcia-Buey, L.; Munoz de Rueda, P.; Rodrigo, L.; Vidal-Castineira, J. R.; Salmeron, J.; Moreno-Otero, R.; Sanz-Cameno, P. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy Genes Immun. 2013, 14, 317-324
14. Kozlov, M. V.; Kleymenova, A. A.; Romanova, L. I.; Konduktorov, K. A.; Smirnova, O. A.; Prasolov, V. S.; Kochetkov, S. N. Benzohydroxamic acids as potent and selective anti-HCV agents Bioorg. Med. Chem. Lett. 2013, 23, 5936-5940
15. Sato, A.; Saito, Y.; Sugiyama, K.; Sakasegawa, N.; Muramatsu, T.; Fukuda, S.; Yoneya, M.; Kimura, M.; Ebinuma, H.; Hibi, T.; Ikeda, M.; Kato, N.; Saito, H. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication J. Cell. Biochem. 2013, 114, 1987-1996
16. Tomassini, J. E.; Getty, K.; Stahlhut, M. W.; Shim, S.; Bhat, B.; Eldrup, A. B.; Prakash, T. P.; Carroll, S. S.; Flores, O.; MacCoss, M.; McMasters, D. R.; Migliaccio, G.; Olsen, D. B. Inhibitory effect of 2-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells Antimicrob. Agents Chemother. 2005, 49, 2050-2058
17. Chen, L.; Wilson, D.; Jayaram, H. N.; Pankiewicz, K. W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment J. Med. Chem. 2007, 50, 6685-6691
18. Belinostat. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm.
19. Khot, A.; Dickinson, M.; Prince, H. M. Panobinostat in lymphoid and myeloid malignancies Expert Opin. Invest. Drugs 2013, 22, 1211-1223
20. Knipstein, J.; Gore, L. Entinostat for treatment of solid tumors and hematologic malignancies Expert Opin. Invest. Drugs 2011, 20, 1455-1467
21. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 2008, 22, 1026-1034
22. Kalin, J. H.; Butler, K. V.; Akimova, T.; Hancock, W. W.; Kozikowski, A. P. Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells J. Med. Chem. 2012, 55, 639-651
23. Lobera, M.; Madauss, K. P.; Pohlhaus, D. T.; Wright, Q. G.; Trocha, M.; Schmidt, D. R.; Baloglu, E.; Trump, R. P.; Head, M. S.; Hofmann, G. A.; Murray-Thompson, M.; Schwartz, B.; Chakravorty, S.; Wu, Z.; Mander, P. K.; Kruidenier, L.; Reid, R. A.; Burkhart, W.; Turunen, B. J.; Rong, J. X.; Wagner, C.; Moyer, M. B.; Wells, C.; Hong, X.; Moore, J. T.; Williams, J. D.; Soler, D.; Ghosh, S.; Nolan, M. A. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group Nat. Chem. Biol. 2013, 9, 319-325
24. Silvaggi, N. R.; Boldt, G. E.; Hixon, M. S.; Kennedy, J. P.; Tzipori, S.; Janda, K. D.; Allen, K. N. Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility Chem. Biol. 2007, 14, 533-542
25. Boldt, G. E.; Kennedy, J. P.; Janda, K. D. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry Org. Lett. 2006, 8, 1729-1732
26. Capek, P.; Zhang, Y.; Barlow, D. J.; Houseknecht, K. L.; Smith, G. R.; Dickerson, T. J. Enhancing the pharmacokinetic properties of botulinum neurotoxin serotype A protease inhibitors through rational design ACS Chem. Neurosci. 2011, 2, 288-293
27. Yao, F.; Liu, J. Q.; Cai, M. Z. Heck arylation of conjugated alkenes with aryl bromides or chlorides catalyzed by immobilization of palladium in MCM-41 Catal. Lett. 2013, 143, 681-686
28. van den Berg, D.; Zoellner, K. R.; Ogunrombi, M. O.; Malan, S. F.; TerreBlanche, G.; Castagnoli, N.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues Bioorg. Med. Chem. 2007, 15, 3692-3702
29. la Buscato, E.; Buttner, D.; Bruggerhoff, A.; Klingler, F. M.; Weber, J.; Scholz, B.; Zivkovic, A.; Marschalek, R.; Stark, H.; Steinhilber, D.; Bode, H. B.; Proschak, E. From a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties ChemMedChem 2013, 8, 919-923
30. Thaler, F.; Colombo, A.; Mai, A.; Amici, R.; Bigogno, C.; Boggio, R.; Cappa, A.; Carrara, S.; Cataudella, T.; Fusar, F.; Gianti, E.; di Ventimiglia, S. J.; Moroni, M.; Munari, D.; Pain, G.; Regalia, N.; Sartori, L.; Vultaggio, S.; Dondio, G.; Gagliardi, S.; Minucci, S.; Mercurio, C.; Varasi, M. Synthesis and biological evaluation of N -hydroxyphenylacrylamides and N -hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors J. Med. Chem. 2010, 53, 822-839
31. Yadav, R. K.; Gupta, S. P.; Sharma, P. K.; Patil, V. M. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: A review Curr. Med. Chem. 2011, 18, 1704-1722
32. Brown, S.; Meroueh, S. O.; Fridman, R.; Mobashery, S. Quest for selectivity in inhibition of matrix metalloproteinases Curr. Top. Med. Chem. 2004, 4, 1227-1238
33. Li, N. G.; Shi, Z. H.; Tang, Y. P.; Wei, L.; Lian, Y.; Duan, J. A. Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis Curr. Med. Chem. 2012, 19, 2924-2956
34. Usachova, N.; Leitis, G.; Jirgensons, A.; Kalvinsh, I. Synthesis of hydroxamic acids by activation of carboxylic acids with N, N -carbonyldiimidazole: exploring the efficiency of the method Synth. Commun. 2010, 40, 927-935
35. Abe, M.; Nishikawa, K.; Fukuda, H.; Nakanishi, K.; Tazawa, Y.; Taniguchi, T.; Park, S. Y.; Hiradate, S.; Fujii, Y.; Okuda, K.; Shindo, M. Key structural features of cis-cinnamic acid as an allelochemical Phytochemistry 2012, 84, 56-67
36. Groundwater, P. W.; Garnett, I.; Morton, A. J.; Sharif, T.; Coles, S. J.; Hursthouse, M. B.; Nyerges, M.; Anderson, R. J.; Bendell, D.; McKillop, A.; Zhang, W. M. A novel synthesis of imidazoles via the cycloaddition of nitrile ylides to their imidoyl chloride precursors J. Chem. Soc., Perkin Trans. 1 2001, 2781-2787
37. Day, J. A.; Cohen, S. M. Investigating the selectivity of metalloenzyme inhibitors J. Med. Chem. 2013, 56, 7997-8007
38. Sechi, M.; Derudas, M.; Dallocchio, R.; Dessi, A.; Bacchi, A.; Sannia, L.; Carta, F.; Palomba, M.; Ragab, O.; Chan, C.; Shoemaker, R.; Sei, S.; Dayam, R.; Neamati, N. Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors J. Med. Chem. 2004, 47, 5298-5310
39. Olgen, S.; Kaessler, A.; Nebioglu, D.; Jose, J. New potent indole derivatives as hyaluronidase inhibitors Chem. Biol. Drug Des. 2007, 70, 547-551
40. Antilla, J. C.; Klapars, A.; Buchwald, S. L. The copper-catalyzed N-arylation of indoles J. Am. Chem. Soc. 2002, 124, 11684-11688
41. Vieira, T. O.; Meaney, L. A.; Shi, Y. L.; Alper, H. Tandem palladium-catalyzed N,C-coupling/carbonylation sequence for the synthesis of 2-carboxyindoles Org. Lett. 2008, 10, 4899-4901
42. Engel-Andreasen, J.; Shimpukade, B.; Ulven, T. Selective copper catalysed aromatic N-arylation in water Green Chem. 2013, 15, 336-340
43. Olgen, S.; Akaho, E.; Nebioglu, D. Synthesis and receptor docking studies of N-substituted indole-2-carboxylic acid esters as a search for COX-2 selective enzyme inhibitors Eur. J. Med. Chem. 2001, 36, 747-770
44. Nomura, D. K.; Dix, M. M.; Cravatt, B. F. Activity-based protein profiling for biochemical pathway discovery in cancer Nat. Rev. Cancer 2010, 10, 630-638
45. Tanaka, K.; Matsuo, K.; Nakanishi, A.; Hatano, T.; Izeki, H.; Ishida, Y.; Mori, W. Syntheses and anti-inflammatory and analgesic activities of hydroxamic acids and acid hydrazides Chem. Pharm. Bull. 1983, 31, 2810-2819
46. Wagh, R. D.; Mahajan, H. S.; Kaskhedikar, S. G. Synthesis and antioxidant activity of substituted phenylalkene hydroxamic acids Asian J. Chem. 2007, 19, 4188-4192
47. Peh, G. R.; Kantchev, E. A. B.; Zhang, C.; Ying, J. Y. N-heterocycle carbene (NHC)-ligated cyclopalladated N, N -dimethylbenzylamine: a highly active, practical and versatile catalyst for the Heck-Mizoroki reaction Org. Biomol. Chem. 2009, 7, 2110-2119
48. Witter, D. J.; Belvedere, S.; Chen, L.; Secrist, J. P.; Mosley, R. T.; Miller, T. A. Benzo[ b ]thiophene-based histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 4562-4567
49. Choi, J.; Park, J. G.; Pang, Y. P. Convenient synthesis of a library of discrete hydroxamic acids using the hydroxythiophenol (Marshall) resin Tetrahedron Lett. 2008, 49, 1103-1106
50. Summers, J. B.; Kim, K. H.; Mazdiyasni, H.; Holms, J. H.; Ratajczyk, J. D.; Stewart, A. O.; Dyer, R. D.; Carter, G. W. Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships J. Med. Chem. 1990, 33, 992-998
51. Chen, Y. L.; Tang, J.; Kesler, M. J.; Sham, Y. Y.; Vince, R.; Geraghty, R. J.; Wang, Z. The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus Bioorg. Med. Chem. 2012, 20, 467-479
52. Chen, Y. L.; Zacharias, J.; Vince, R.; Geraghty, R. J.; Wang, Z. C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus Bioorg. Med. Chem. 2012, 20, 4790-4800
53. Schmittgen, T. D.; Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method Nat. Protoc. 2008, 3, 1101-1108